I am a
Home I AM A Search Login

Papers of the Week


Papers: 24 Apr 2021 - 30 Apr 2021


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2021 Apr 23


BMC Neurol


21


1

Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.

Authors

Kuruppu DK, Tobin J, Dong Y, Aurora SK, Yunes-Medina L, Green LA
BMC Neurol. 2021 Apr 23; 21(1):175.
PMID: 33892641.

Abstract

Galcanezumab is a calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) indicated for the preventive treatment of migraine. While galcanezumab has demonstrated efficacy in patients who did not respond to prior preventive medications in general, its efficacy in patients who did not benefit from individual, commonly prescribed preventive treatments due to inadequate efficacy or safety/tolerability remains unknown.